导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -3.92% | 3297/4773 |
| 近一周 | -1.37% | 2082/5465 |
| 近一月 | -6.88% | 4360/5421 |
| 近一季 | 9.72% | 208/5231 |
| 近半年 | -3.10% | 2393/4920 |
| 近一年 | -15.82% | 3782/4394 |
| 近两年 | 16.73% | 2703/2954 |
| 近三年 | -11.02% | 2045/2253 |
| 成立以来 | -13.90% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.62% 2390/4961 |
-6.39% 3690/5312 |
- - |
- - |
| 2025 | 5.66% 2990/4813 |
0.90% 1741/3635 |
2.17% 1793/4076 |
16.49% 2644/4524 |
-12.02% 4232/4813 |
| 2024 | -12.44% 2379/3463 |
-10.67% 2364/2808 |
-8.93% 2304/3014 |
18.78% 933/3129 |
-9.39% 2925/3463 |
| 2023 | -10.07% 1260/2656 |
0.42% 1731/2280 |
-7.74% 1900/2385 |
-0.93% 466/2515 |
-2.02% 405/2655 |
| 2022 | -19.48% 854/2207 |
-12.18% 582/1919 |
0.33% 1559/2016 |
-16.58% 1471/2113 |
9.55% 207/2208 |
| 2021 | -4.82% 961/1822 |
-1.54% 510/1255 |
16.48% 201/1330 |
-13.36% 1339/1466 |
-4.20% 1472/1822 |
| 2020 | - - |
- - |
- - |
7.84% 757/1164 |
7.29% 720/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 东财医药A VS. 长安沪深300非周期A(740101) |